Get the Stockscreener App
7.74
0.77%
-0.06
After Hours:
7.74
Verastem Inc stock is traded at $7.74, with a volume of 1.06M.
It is down -0.77% in the last 24 hours and up +9.32% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$7.80
Open:
$7.86
24h Volume:
1.06M
Relative Volume:
0.43
Market Cap:
$700.96M
Revenue:
$30.91M
Net Income/Loss:
$-209.47M
P/E Ratio:
-2.3258
EPS:
-3.3279
Net Cash Flow:
$-147.13M
1W Performance:
+4.03%
1M Performance:
+9.32%
6M Performance:
+52.06%
1Y Performance:
-10.10%
1-Day Range:
$7.67
$7.89
1-Week Range:
$7.50
$8.645
52-Week Range:
$3.43
$10.82
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
7.74 | 700.96M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Feb-04-26 | Initiated | H.C. Wainwright | Buy |
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Understanding the Setup: (VSTM) and Scalable Risk - Stock Traders Daily
Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance UK
Verastem, Inc. (VSTM) Stock Price, News, Quote & History - ca.finance.yahoo.com
Verastem to present cancer treatment study data at IGCS meeting - Investing.com
Verastem to present cancer treatment study data at IGCS meeting By Investing.com - Investing.com Canada
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire
Form 4 Verastem Inc For: 23 September By Investing.com - Investing.com Canada
Form 4 Verastem Inc For: 23 September - Investing.com India
Verastem CFO Daniel Calkins sells $423 in company stock - Investing.com
Verastem CFO Daniel Calkins sells $423 in company stock By Investing.com - Investing.com Canada
Verastem (VSTM) CFO Daniel Calkins Sells 55 Shares, Insider Owne - GuruFocus
After selling 55 shares, Verastem (VSTM) CFO Daniel Calkins directly owned 118,014 shares. - Stock Titan
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - TradingView
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Verastem Inc. Share PriceVSTM, RNS News, Articles, Quotes, & Charts (NASDAQ:VSTM) - Proactive financial news
RBC Capital Keeps Their Buy Rating on Verastem (VSTM) - The Globe and Mail
Verastem Stock Price Forecast. Should You Buy VSTM? - StockInvest.us
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - marketscreener.com
Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 94% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem Repeat Insider Selling Not A Positive Indicator - Moomoo
Wolfe Research Initiates Verastem at Outperform - Yahoo Finance
Wolfe Research Maintains Verastem(VSTM.US) With Buy Rating - Moomoo
(VSTM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
H.C. Wainwright reiterates Verastem stock rating on cancer trial data By Investing.com - Investing.com Canada
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus
SpaceX Stock Price Today | SPCX Ticker, News, Retail Sentiment - Stocktwits
Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com India
VSTM: Verastem Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - The Globe and Mail
Verastem (VSTM) Plans Investor Event to Reveal Preliminary Data on VS-7375 Amid Mixed Market Signals - GuruFocus
A cancer drug’s first broad safety update is set for Oct. 14 from Verastem - Stock Titan
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers - Business Wire
VSTM 8-K FilingsVerastem, Inc. SEC 8-K - Stock Titan
(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Verastem Oncology to Participate in Upcoming September Investor Conferences - Yahoo! Finance Canada
Boston and New York are set for Verastem Oncology appearances in September. - Stock Titan
Verastem Inc. (VSTM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verastem Inc. (VSTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform (NASDAQ:VSTM) - Seeking Alpha
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views - Yahoo Finance
Verastem (VSTM) Watch: Records a 1.03% Increase to $6.89 on the Day; Technical View - vinanet.vn
Verastem (NASDAQ:VSTM) Shares Down 8.6%Should You Sell? - MarketBeat
Verastem (VSTM) Q2 2026 Earnings Call Transcript - AOL.com
VSTM | Verastem, Inc. FinancialsRevenue Breakdown - quiverquant.com
Verastem (NASDAQ:VSTM) Shares Up 6.4%What's Next? - MarketBeat
Precision Trading with Verastem Inc. (VSTM) Risk Zones - news.stocktradersdaily.com
Verastem (VSTM) Slips 1.35% to $6.58 as Biotech Stock Holds Above Key SupportDebt Free Companies - vinanet.vn
Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):